Abstract
The development of the filtration barrier is part of a complex sequence of steps proceeding from the early nephron anlage (renal vesicle) via the comma- and S-shaped body to the capillary loop stage and mature glomerulus. The main players are the podocytes (already in the stage of presumptive podocytes), which hold the commander function in this process, and the endothelial and the mesangial cells. A decisive role is also played by the GBM; its change in composition during the developmental process is a precondition for the final maturation of the podocytes, i.e. for the formation of the foot processes and, clearly subsequent, the slit membrane. Failure in the consecutive developmental stages due to genetic mutations or manipulations leads to characteristic hereditary diseases of increasing severity. The last step in this development, the formation of the slit membrane, marks a caesura between diseases with early and late onset; all disorders without a properly developed slit membrane start prenatally or at birth.
Journal Section:
Paper
References
1.
Saxen L, Sariola H, Lehtonen E: Sequential cell and tissue interactions governing organogenesis of the kidney. Anat Embryol 1986;175:1–6.
[PubMed]
2.
Abrahamson D: Glomerulogenesis in the developing kidney. Semin Nephrol 1991;11:375–389.
[PubMed]
3.
Discenza M, He S, Lee T, Chu L, Bolon B, Goodyer P, Eccles M, Pelletier J: WT1 is a modifier of the Pax2 mutant phenotype: cooperation and interaction between WT1 and Pax2. Oncogene 2003;22:8145–8155.
[PubMed]
4.
Hanson J, Gorman J, Reese J, Fraizer G: Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci 2007;1:2279–2290.
5.
Eremina V, Haigh J, Nagy A, Kikkawa Y, Miner J, Quaggin S: The role of VEGF-A in glomerular angiogenesis. J Am Soc Nephrol 2002;13:100A.
6.
Eremina V, Quaggin S: The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004;13:9–15.
[PubMed]
7.
Betzholtz C, Lindblom P, Bjarnegard M, Enge M, Gerhardt H, Lindahl P: Role of platelet-derived growth factor in mesangium development and vasculopathies: lessons from platelet-derived growth factor and platelet-derived growth factor receptor mutations in mice. Curr Opin Nephrol Hypertens 2005;13:45–52.
8.
Miner JH: Building the glomerulus: a matricentric view. J Am Soc Nephrol 2005;16:857–861.
[PubMed]
9.
Kikkawa Y, Virtanen I, Miner JH: Mesangial cells organize the glomerular capillaries by adhering to the G domain of laminin alpha5 in the glomerular basement membrane. J Cell Biol 2003;161:187–196.
[PubMed]
10.
Reeves W, Kanwar Y, Farquhar M: Assembly of the glomerular filtration surface: differentiation of anionic sites in glomerular capillaries of newborn rat kidney. J Cell Biol 1980;85:735–753.
[PubMed]
11.
Abrahamson D, Robert B: Derivation and differentiation of glomerular endothelial cells. Nephrol Dial Transplant 2003;18:vi2–vi7.
12.
Kriz W, Haehnel B, Hosser H, Ostendorf T, Kränzlin B, Gretz N, Shimizu F, Floege J: Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis. J Am Soc Nephrol 2003;14:1904–1926.
[PubMed]
13.
Reeves W, Caulfield J, Farquhar M: Differentiation of epithelial foot processes and filtration slits: sequential appearance of occluding junctions, epithelial polyanion, and slit membranes in developing glomeruli. Lab Invest 1978;39:90–100.
[PubMed]
14.
Hastie N: The genetics of Wilms’ tumor: a case of disrupted development. Annu Rev Genet 1994;28:523–558.
[PubMed]
15.
Kreidberg J, Sariola H, Loring J, Maeda M, Pelletier J, Housman D, Jaenisch R: WT-1 is required for early kidney development. Cell 1993;74:679–691.
[PubMed]
16.
Habib R, Loirat C, Gubler M, Niaudet P, Bensman A, Levy M, Broyer M: The nephropathy associated with male pseudohermaphroditism and Wilms’ tumor. Drash syndrome: a distinctive glomerular lesion – report of 10 cases. Clin Nephrol 1985;24:269–278.
[PubMed]
17.
Yang Y, Jeanpierre C, Dressler G, Lacoste M, Nidaudet P, Gubler M: WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. Am J Pathol 1999;154:181–192.
[PubMed]
18.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–716.
[PubMed]
19.
Miner JH, Morello R, Andrews KL, Li C, Antignac C, Shaw AS, Lee B: Transcriptional induction of slit diaphragm genes by Lmx1b is required in podocyte differentiation. J Clin Invest 2002;109:1065–1072.
[PubMed]
20.
Rohr C, Prestel J, Heidet L, Hosser H, Kriz W, Johnson R, Antignac C, Witzgall R: The LIM-homeodomain transcription factor Lmx1b plays a crucial role in podocytes. J Clin Invest 2002;109:1073–1082.
[PubMed]
21.
Miner JH, Li C: Defective glomerulogenesis in the absence of laminin alpha5 demonstrates a developmental role for the kidney glomerular basement membrane. Dev Biol 2000;217:278–289.
[PubMed]
22.
Kreidberg J, Donovan M, Goldstein S, Rennke H, Shepherd K, Jones R, Jaenisch R: Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996;122:3537–3547.
[PubMed]
23.
Doyonnas R, Kershaw D, Duhme C, Merkens H, Chelliah S, Graf T, McNagny K: Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 2001;194:13–27.
[PubMed]
24.
Quaggin S, Schwartz L, Cui S, Igarashi P, Deimling J, Post M, Rossant J: The basic-helix-loop-helix protein Pod1 is critically important for kidney and lung organogenesis. Development 1999;126:5771–5783.
[PubMed]
25.
Ciani L, Patel A, Allen N, ffrench-Constant C: Mice lacking the giant protocadherin mFAT1 exhibit renal slit junction abnormalities and a partially penetrant cyclopia and anophthalmia phenotype. Mol Cell Biol 2003;23:3575–3582.
[PubMed]
26.
Kestila M, Lenkkeri U, Männikkö M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan C, Peltonen L, Holmberg C, Olsen A, Tryggvason K: Positionally cloned gene for a novel glomerular protein – nephrin – is mutated in congenital nephrotic syndrome. Mol Cell 1998;1:575–582.
[PubMed]
27.
Kuusniemi A-M, Merenimes J, Lahdenkari A-T, Holmberg C, Salmela K, Karikoski R, Rapola J, Jalanko H: Glomerular sclerosis in kidneys with congenital nephrotic syndrome (NPHS1). Kidney Int 2006;70:1423–1431.
[PubMed]
28.
Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler M, Niaudet P, Antignac C: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000;24:349–354.
[PubMed]
29.
Putaala H, Soininen R, Kilpelainen P, Wartiovaara J, Tryggvason K: The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 2001;10:1–8.
[PubMed]
30.
Rantanen M, Palmen T, Patari A, Ahola H, Lehtonen S, Astrom E, Floss T, Vauti F, Wurst W, Ruiz P, Kerjaschki D, Holthofer H: Nephrin TRAP mice lack slit diaphragms and show fibrotic glomeruli and cystic tubular lesions. J Am Soc Nephrol 2002;13:1586–1594.
[PubMed]
31.
Roselli S, Heidet L, Sich M, Henger A, Kretzler M, Gubler M, Antignac C: Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell Biol 2005;24:550–560.
32.
Donoviel D, Freed D, Vogel H, Potter D, Hawkins E, Barrish J, Mathur B, Turner C, Geske R, Montgomery C, Starbuck M, Brandt M, Gupta A, Ramirez-Soliz R, Zambrowicz B: Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to nephrin. Mol Cell Biol 2001;21:4829–4836.
[PubMed]
33.
Zenker M, Aigner T, Wendler O, Tralau T, Müntefering H, Fenski R, Pitz S, Schumacher V, Royer-Pokora B, Wühl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dötsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann L, Reis A: Human laminin β2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 2004;13:2625–2632.
[PubMed]
34.
Noakes PG, Miner JH, Gautam M, Cunningham JM, Sanes JR, Merlie JP: The renal glomerulus of mice lacking s-laminin/laminin beta 2: nephrosis despite molecular compensation by laminin beta 1. Nat Genet 1995;10:400–406.
[PubMed]
35.
Jarad G, Cunningham J, Shaw AS, Miner JH: Proteinuria precedes podocyte abnormalities in Lamb2–/– mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest 2006;116:2272–2279.
[PubMed]
36.
Kaplan C, Kim S, North K, Rennke H, Correia L, Tong H, Mathis B, Rodríguez-Pérez J, Allen P, Beggs A, Pollak M: Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000;24:251–256.
[PubMed]
37.
Arrondel C, Vodovar N, Knebelmann B, Grunfeld J, Gubler M, Antignac C, Heidet L: Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol 2002;13:65–74.
[PubMed]
38.
Reiser J, Polu K, Moller C, Kenlan P, Altintas M, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith P, Clapham D, Pollak M: TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005;37:739–744.
[PubMed]
39.
Winn M, Conlon P, Lynn K, Farrington M, Creazzo T, Hawkins A, Daskalakis N, Kwan S, Ebersviller S, Burchette J, Pericak-Vance M, Howell D, Vance J, Rosenberg P: A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005;308:1801–1804.
[PubMed]
40.
Barbaux S, Niaudet P, Gubler M, Grunfeld J, Jaubert F, Kuttenn F, Fekete C, Souleyreau-Therville N, Thibaud E, Fellous M, McElreavey K: Donor splice-site mutations in WT-1 are responsible for Frasier syndrome. Nat Genet 1997;17:467–470.
41.
Bennett W, Musgrave J, Campbell R, Elliot D, Cox R, Brooks R, Lovrien E, Beals R, Porter G: The nephropathy of the nail-patella syndrome: clinicopathologic analysis of 11 kindred. Am J Med 1973;54:304–319.
[PubMed]
42.
Kos C, Le T, Sinha S, Henderson J, Kim S, Sugimoto H, Kalluri R, Gerszten R, Pollak M: Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest 2003;111:1683–1690.
[PubMed]
43.
Asanuma K, Kim K, Oh J, Giardino L, Chabanis S, Faul C, Reiser J, Mundel P: Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest 2005;1:1.
44.
Shih N-Y, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS: Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999;286:312–315.
[PubMed]
45.
Kashtan C: Animal models of Alport syndrome. Nephrol Dial Transplant 2002;17:1359–1361.
[PubMed]
46.
Hammes A, Guo J, Lutsch G, Leheste J, Landrock D, Ziegler U, Gubler M, Schedl A: Two splice variants of the Wilms’ tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 2001;106:319–329.
[PubMed]
47.
Yao J, Le T, Kos C, Henderson J, Allen P, Denker B, Pollak M: Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biology 2004;2:0787–0794.
48.
Kriz W: TRPC6 – a new podocyte gene involved in focal segmental glomerulosclerosis. Trends Mol Med 2005;11:527–530.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
